AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks Biotherapeutics (TRAX) spinoff, and thus now operates as a royalty management company, exclusively responsible for its financial collaborations with GSK and Vanda Pharmaceuticals.
Ultimately, Piper Sandler stated that it believes the separation makes sense, as it effectively works to protect and optimize the value of the royalty business. This is fundamentally distinct from the biopharma development company.
In another development, AnaptysBio, Inc. (NASDAQ:ANAB) announced on April 24 that the Delaware Chancery Court has dismissed Tesaro’s anticipatory breach of contract claim against the company, with the ruling agreeing with Anaptys’ position that it has never repudiated the Collaboration and Exclusive License Agreement with Tesaro regarding the development and commercialization of Jemperli. Tesaro is a subsidiary of GSK.
AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company that exclusively manages the financial collaborations from Jemperli with GSK and imsidolimab with Vanda.
While we acknowledge the potential of ANAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
